Skip to main content
Key Specialties
Cardiology Diabetology Endocrinology Gastroenterology Geriatrics and Gerontology Gynecology and Obstetrics Hematology Infectious Disease Internal Medicine Nephrology Neurology Oncology Pediatrics Respiratory Medicine Rheumatology Surgery
Congress Coverage
2024 ACC Congress 2023 ESMO Congress 2023 EASD Congress 2023 ERS Congress 2023 ESC Congress 2023 EHA Congress 2023 ASCO Annual Meeting
Clinical Collections
Advances in Alzheimer’s

At a glance: The ONWARDS insulin icodec trials

A round-up of the ONWARDS phase 3 clinical trials evaluating the novel weekly insulin icodec in people with diabetes.
ADVANCED SEARCH
Log in
Top
European Journal of Epidemiology
Published in: European Journal of Epidemiology 4/2019

Open Access 01-04-2019 | Insulins | DIABETES MELLITUS

Protein markers and risk of type 2 diabetes and prediabetes: a targeted proteomics approach in the KORA F4/FF4 study

Authors: Cornelia Huth, Christine von Toerne, Florian Schederecker, Tonia de las Heras Gala, Christian Herder, Florian Kronenberg, Christa Meisinger, Wolfgang Rathmann, Wolfgang Koenig, Melanie Waldenberger, Michael Roden, Annette Peters, Stefanie M. Hauck, Barbara Thorand

Published in: European Journal of Epidemiology | Issue 4/2019

Login to get access

Abstract

The objective of the present study was to identify proteins that contribute to pathophysiology and allow prediction of incident type 2 diabetes or incident prediabetes. We quantified 14 candidate proteins using targeted mass spectrometry in plasma samples of the prospective, population-based German KORA F4/FF4 study (6.5-year follow-up). 892 participants aged 42–81 years were selected using a case-cohort design, including 123 persons with incident type 2 diabetes and 255 persons with incident WHO-defined prediabetes. Prospective associations between protein levels and diabetes, prediabetes as well as continuous fasting and 2 h glucose, fasting insulin and insulin resistance were investigated using regression models adjusted for established risk factors. The best predictive panel of proteins on top of a non-invasive risk factor model or on top of HbA1c, age, and sex was selected. Mannan-binding lectin serine peptidase (MASP) levels were positively associated with both incident type 2 diabetes and prediabetes. Adiponectin was inversely associated with incident type 2 diabetes. MASP, adiponectin, apolipoprotein A-IV, apolipoprotein C-II, C-reactive protein, and glycosylphosphatidylinositol specific phospholipase D1 were associated with individual continuous outcomes. The combination of MASP, apolipoprotein E (apoE) and adiponectin improved diabetes prediction on top of both reference models, while prediabetes prediction was improved by MASP plus CRP on top of the HbA1c model. In conclusion, our mass spectrometric approach revealed a novel association of MASP with incident type 2 diabetes and incident prediabetes. In combination, MASP, adiponectin and apoE improved type 2 diabetes prediction beyond non-invasive risk factors or HbA1c, age and sex.
Appendix
Available only for authorised users
Literature
1.
Ogurtsova K, da Rocha Fernandes JD, Huang Y, Linnenkamp U, Guariguata L, Cho NH, et al. IDF diabetes atlas: global estimates for the prevalence of diabetes for 2015 and 2040. Diabetes Res Clin Pract. 2017;128:40–50.CrossRefPubMed
2.
Dorcely B, Katz K, Jagannathan R, Chiang SS, Oluwadare B, Goldberg IJ, et al. Novel biomarkers for prediabetes, diabetes, and associated complications. Diabetes Metab Syndr Obes. 2017;10:345–61.CrossRefPubMedPubMedCentral
3.
Abbasi A, Sahlqvist AS, Lotta L, Brosnan JM, Vollenweider P, Giabbanelli P, et al. A systematic review of biomarkers and risk of incident type 2 diabetes: an overview of epidemiological, prediction and aetiological research literature. PLoS ONE. 2016;11:e0163721.CrossRefPubMedPubMedCentral
4.
Herder C, Kannenberg JM, Niersmann C, Huth C, Carstensen-Kirberg M, Wittenbecher C, et al. Independent and opposite associations of serum levels of omentin-1 and adiponectin with increases of glycaemia and incident type 2 diabetes in an older population: KORA F4/FF4 study. Eur J Endocrinol. 2017;177:277–86.CrossRefPubMed
5.
Huth C, Beuerle S, Zierer A, Heier M, Herder C, Kaiser T, et al. Biomarkers of iron metabolism are independently associated with impaired glucose metabolism and type 2 diabetes: the KORA F4 study. Eur J Endocrinol. 2015;173:643–53.CrossRefPubMed
6.
Gall WE, Beebe K, Lawton KA, Adam KP, Mitchell MW, Nakhle PJ, et al. Alpha-hydroxybutyrate is an early biomarker of insulin resistance and glucose intolerance in a nondiabetic population. PLoS ONE. 2010;5:e10883.CrossRefPubMedPubMedCentral
7.
Nowak C, Sundstrom J, Gustafsson S, Giedraitis V, Lind L, Ingelsson E, et al. Protein biomarkers for insulin resistance and type 2 diabetes risk in two large community cohorts. Diabetes. 2016;65:276–84.PubMed
8.
Kollerits B, Lamina C, Huth C, Marques-Vidal P, Kiechl S, Seppala I, et al. Plasma concentrations of afamin are associated with prevalent and incident type 2 diabetes: a pooled analysis in more than 20,000 individuals. Diabetes Care. 2017;40:1386–93.CrossRefPubMed
9.
Peddinti G, Cobb J, Yengo L, Froguel P, Kravic J, Balkau B, et al. Early metabolic markers identify potential targets for the prevention of type 2 diabetes. Diabetologia. 2017;60:1740–50.CrossRefPubMedPubMedCentral
10.
Salomaa V, Havulinna A, Saarela O, Zeller T, Jousilahti P, Jula A, et al. Thirty-one novel biomarkers as predictors for clinically incident diabetes. PLoS ONE. 2010;5:e10100.CrossRefPubMedPubMedCentral
11.
Bongaerts BW, Rathmann W, Heier M, Kowall B, Herder C, Stockl D, et al. Older subjects with diabetes and prediabetes are frequently unaware of having distal sensorimotor polyneuropathy: the KORA F4 study. Diabetes Care. 2013;36:1141–6.CrossRefPubMedPubMedCentral
12.
Anderson JP, Parikh JR, Shenfeld DK, Ivanov V, Marks C, Church BW, et al. Reverse engineering and evaluation of prediction models for progression to type 2 diabetes: an application of machine learning using electronic health records. J Diabetes Sci Technol. 2015;10:6–18.CrossRefPubMedPubMedCentral
13.
Herder C, Kowall B, Tabak AG, Rathmann W. The potential of novel biomarkers to improve risk prediction of type 2 diabetes. Diabetologia. 2014;57:16–29.CrossRefPubMed
14.
American Diabetes Association. Diagnosis and classification of diabetes mellitus. Diabetes Care. 2014;37(Suppl 1):S81–90.CrossRef
15.
Kahn SE, Cooper ME, Del Prato S. Pathophysiology and treatment of type 2 diabetes: perspectives on the past, present, and future. Lancet. 2014;383:1068–83.CrossRef
16.
Paprott R, Muhlenbruch K, Mensink GB, Thiele S, Schulze MB, Scheidt-Nave C, et al. Validation of the German diabetes risk score among the general adult population: findings from the German Health Interview and Examination Surveys. BMJ Open Diabetes Res Care. 2016;4:e000280.CrossRefPubMedPubMedCentral
17.
Nauck M, Petermann A, Müller-Wieland D, Kerner W, Müller UA, Landgraf R, et al. Definition, Klassifikation und Diagnostik des Diabetes mellitus. Diabetologie und Stoffwechsel. 2017;12:S78–81.
18.
Nordestgaard BG, Langsted A, Mora S, Kolovou G, Baum H, Bruckert E, et al. Fasting is not routinely required for determination of a lipid profile: clinical and laboratory implications including flagging at desirable concentration cut-points-a joint consensus statement from the European Atherosclerosis Society and European Federation of Clinical Chemistry and Laboratory Medicine. Eur Heart J. 2016;37:1944–58.CrossRefPubMedPubMedCentral
19.
Waugh NR, Shyangdan D, Taylor-Phillips S, Suri G, Hall B. Screening for type 2 diabetes: a short report for the National Screening Committee. Health Technol Assess. 2013;17:1–90.PubMedPubMedCentral
20.
Laxy M, Knoll G, Schunk M, Meisinger C, Huth C, Holle R. Quality of diabetes care in Germany improved from 2000 to 2007 to 2014, but improvements diminished since 2007. Evidence from the population-based KORA studies. PLoS ONE. 2007;2016(11):e0164704.
21.
WHO. Definition, diagnosis and classification of diabetes mellitus and its complications. Report of a WHO consultation. Part 1: diagnosis and classification of diabetes mellitus. WHO Department of Noncommunicable Disease Surveillance, Geneva, Switzerland;1999. p. 1–59.
22.
WHO. Global report on diabetes. Geneva, Switzerland: WHO Press; 2006.
23.
von Toerne C, Huth C, de Las Heras Gala T, Kronenberg F, Herder C, Koenig W, et al. MASP1, THBS1, GPLD1 and ApoA-IV are novel biomarkers associated with prediabetes: the KORA F4 study. Diabetologia. 2016;59:1882–92.CrossRef
24.
van Buuren S, Groothuis-Oudshoom K. Mice: multivariate imputation by chained equations in R. J Stat Softw. 2011;45:1–67.CrossRef
25.
Thiel S, Jensen L, Degn SE, Nielsen HJ, Gal P, Dobo J, et al. Mannan-binding lectin (MBL)-associated serine protease-1 (MASP-1), a serine protease associated with humoral pattern-recognition molecules: normal and acute-phase levels in serum and stoichiometry of lectin pathway components. Clin Exp Immunol. 2012;169:38–48.CrossRefPubMedPubMedCentral
26.
Abbatiello SE, Mani DR, Keshishian H, Carr SA. Automated detection of inaccurate and imprecise transitions in peptide quantification by multiple reaction monitoring mass spectrometry. Clin Chem. 2010;56:291–305.CrossRefPubMed
27.
R Core Team. R: a language and environment for statistical computing. R Foundation for Statistical Computing; 2017.
28.
Pencina MJ, D’Agostino RB Sr, Steyerberg EW. Extensions of net reclassification improvement calculations to measure usefulness of new biomarkers. Stat Med. 2011;30:11–21.CrossRef
29.
Pickering JW, Endre ZH. New metrics for assessing diagnostic potential of candidate biomarkers. Clin J Am Soc Nephrol. 2012;7:1355–64.CrossRef
30.
Rathmann W, Kowall B, Heier M, Herder C, Holle R, Thorand B, et al. Prediction models for incident type 2 diabetes mellitus in the older population: KORA S4/F4 cohort study. Diabet Med. 2010;27:1116–23.CrossRefPubMed
31.
Krogh SS, Holt CB, Steffensen R, Funck KL, Hoyem P, Laugesen E, et al. Plasma levels of MASP-1, MASP-3 and MAp44 in patients with type 2 diabetes: influence of glycaemic control, body composition and polymorphisms in the MASP1 gene. Clin Exp Immunol. 2017;189:103–12.CrossRefPubMedPubMedCentral
32.
King BC, Blom AM. Non-traditional roles of complement in type 2 diabetes: metabolism, insulin secretion and homeostasis. Mol Immunol. 2017;84:34–42.CrossRefPubMed
33.
Thiel S. Complement activating soluble pattern recognition molecules with collagen-like regions, mannan-binding lectin, ficolins and associated proteins. Mol Immunol. 2007;44:3875–88.CrossRefPubMed
34.
Dobo J, Schroeder V, Jenny L, Cervenak L, Zavodszky P, Gal P. Multiple roles of complement MASP-1 at the interface of innate immune response and coagulation. Mol Immunol. 2014;61:69–78.CrossRefPubMed
35.
Cortesio CL, Jiang W. Mannan-binding lectin-associated serine protease 3 cleaves synthetic peptides and insulin-like growth factor-binding protein 5. Arch Biochem Biophys. 2006;449:164–70.CrossRefPubMed
36.
Lam CS, Chen MH, Lacey SM, Yang Q, Sullivan LM, Xanthakis V, et al. Circulating insulin-like growth factor-1 and its binding protein-3: metabolic and genetic correlates in the community. Arterioscler Thromb Vasc Biol. 2010;30:1479–84.CrossRefPubMedPubMedCentral
37.
Brahimaj A, Ligthart S, Ikram MA, Hofman A, Franco OH, Sijbrands EJ, et al. Serum levels of apolipoproteins and incident type 2 diabetes: a prospective cohort study. Diabetes Care. 2017;40:346–51.CrossRefPubMed
38.
Onat A, Hergenc G, Ayhan E, Ugur M, Kaya H, Tuncer M, et al. Serum apolipoprotein C-III in high-density lipoprotein: a key diabetogenic risk factor in Turks. Diabet Med. 2009;26:981–8.CrossRefPubMed
39.
40.
Juntti-Berggren L, Berggren PO. Apolipoprotein CIII is a new player in diabetes. Curr Opin Lipidol. 2017;28:27–31.PubMed
41.
Liu C, Feng X, Li Q, Wang Y, Li Q, Hua M. Adiponectin, TNF-alpha and inflammatory cytokines and risk of type 2 diabetes: a systematic review and meta-analysis. Cytokine. 2016;86:100–9.CrossRefPubMed
42.
Schulze MB, Hoffmann K, Boeing H, Linseisen J, Rohrmann S, Mohlig M, et al. An accurate risk score based on anthropometric, dietary, and lifestyle factors to predict the development of type 2 diabetes. Diabetes Care. 2007;30:510–5.CrossRefPubMed
43.
Echouffo-Tcheugui JB, Dieffenbach SD, Kengne AP. Added value of novel circulating and genetic biomarkers in type 2 diabetes prediction: a systematic review. Diabetes Res Clin Pract. 2013;101:255–69.CrossRefPubMed
Metadata
Title
Protein markers and risk of type 2 diabetes and prediabetes: a targeted proteomics approach in the KORA F4/FF4 study
Authors
Cornelia Huth
Christine von Toerne
Florian Schederecker
Tonia de las Heras Gala
Christian Herder
Florian Kronenberg
Christa Meisinger
Wolfgang Rathmann
Wolfgang Koenig
Melanie Waldenberger
Michael Roden
Annette Peters
Stefanie M. Hauck
Barbara Thorand
Publication date
01-04-2019
Publisher
Springer Netherlands
Published in
European Journal of Epidemiology / Issue 4/2019
Print ISSN: 0393-2990
Electronic ISSN: 1573-7284
DOI
https://doi.org/10.1007/s10654-018-0475-8

Other articles of this Issue 4/2019

European Journal of Epidemiology 4/2019 Go to the issue

COMMENTARY

Nutritional epidemiology, extinction or evolution? It is all about balance and moderation

COMMENTARY

Unreformed nutritional epidemiology: a lamp post in the dark forest

META-ANALYSIS

Adherence to the Mediterranean diet and risk of stroke and stroke subtypes

MORTALITY

Red meat, processed meat, and other dietary protein sources and risk of overall and cause-specific mortality in The Netherlands Cohort Study

PERINATAL EPIDEMIOLOGY

Intake of sucrose-sweetened soft beverages during pregnancy and risk of congenital heart defects (CHD) in offspring: a Norwegian pregnancy cohort study

NUTRITIONAL EPIDEMIOLOGY

The application of six dietary scores to a Middle Eastern population: a comparative analysis of mortality in a prospective study